Silica Production Process: Step-by-Step Guide for Fumed, Precipitated and Fused Silica

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silicon Dioxide Manufacturer: Production Methods, Quality Standards and Selection Tips
  • Keywords: hydrophilic silica
  • Published: 2026-11-20 01:29:27
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals

Quartz Powder for Ceramics: Functions, Grades and Particle Size Selection

What Is Hydrophobic Fumed Silica? Surface Treatment, Grades and Applications
Cheng, Y. et al. Spatiotemporally synchronous oxygen self‐supply and reactive oxygen species production on Z‐scheme heterostructures for hypoxic tumor therapy. Adv. Mater. 32, 1908109 (2020). Article CAS Google Scholar
Silica as a Thickening Agent: How It Works in Liquids, Resins and Gels
Lu, J., Liong, M., Zink, J. I. & Tamanoi, F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Tiny 3, 1341-1346 (2007). Article CAS PubMed Google Scholar
Quartz Sand Price: 2026 Price Ranges by Purity and Mesh Size
Best Thixotropic Agent for Epoxy: How Fumed Silica Prevents Sagging

Silica Supplier Indonesia: Market Overview and Sourcing Options

What is silica (SiO₂)?

silica supplier Europe Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.

What is the difference between fumed silica and precipitated silica?

silica density

What drives silica raw material prices?

silica storage conditions The complexity and heterogeneity of the illness microenvironment brings about the problem of poor therapeutic efficiency of single therapies. 465, 466, 467, 468, 469 The current clinical research trend has steadily shifted to multimodal synergistic therapy, as we have noted above with many examples of multimodal synergistic therapy platform construction. In multimodal synergistic therapy, the interaction between different treatment modalities can substantially boost the shortcomings of single therapy, such as overcoming the lack of light penetration depth in PDT, lowering the toxic side effects of chemotherapy, etc., and producing stronger therapeutic outcome through superimposed impacts (namely "1 + 1 > 2"). 470, 471, 472 A prominent feature of multimodal synergistic therapies is the skill to effectively overcome multidrug resistance in diseases, and MSNs are uniquely advantageous in integrating these aforementioned treatment modalities. 369, 473, 474, 475 As an illustration, most of the multidrug resistance generated during chemotherapy of malignant tumors might stem from the overexpression of transmembrane ATP-binding cassette transporter and transmembrane Ca 2+ channels. 476, 477 To address this problem, researchers used mesoporous silica nanocapsules to encapsulate and deliver the cytotoxic drug DOX and T-type Ca 2+ channel siRNA. 478 On the one hand, MSNs can bypass the drug efflux pumps and enter cells directly through endocytosis, increasing the intracellular accumulation of drugs. On the other hand, siRNA can knock down the T-type Ca 2+ channel, leading to a decrease in cytosol Ca 2+ concentration in the cytosol, thus increasing the sensitivity of tumor cells to DOX. Accordingly, the as-designed MSNs-based therapeutic system attained effective chemotherapy-gene therapy to overcome the multidrug resistance in breast cancer. 478 Besides, drug-resistant bacterial infections are a current thorny public health issue. 479 In this regard, researchers have developed a photodynamic combined lysozyme antimicrobial therapy based on upconversion NPs/MSNs nanocomposites to combat the problem of drug-resistant bacterial infections in deep tissues. Briefly, upconversion NPs were sequentially encapsulated with hierarchical coating of dense silica and dendritic mesoporous silica, followed by loading photosensitizers and lysozyme, and finally modified with bacterial hyaluronidase-response valves on the MSNs surface to accomplish controllable release of lysozyme. The results demonstrated that this system promoted direct attack of ROS on cell membranes and cytoplasm through enzymatic cell wall disassembly, resulting in an excellent bactericidal rate toward methicillin-resistant Staphylococcus aureus (> 5 log10 viability reduction). 480

Cite this article: Silica Raw Materials News. "Silica MSDS: How to Read It and What Safety Information to Check ." Published 2026-11-20 01:29:27. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.